ReviewPest management science2022
RNA meets toxicology: efficacy indicators from the experimental design of RNAi studies for insect pest management.
Review in Pest management science, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 28 citations in OpenAlex.
- Chitosan-protected dsRNA increases efficacy against Helicoverpa armigera without compromising biosafety for pollinators.Pest management science · 2026Article
- Article
- Article
- RNA interference (RNAi) for insect pest management: understanding mechanisms, strategies, challenges and future prospects.Biologia futura · 2025Review
- Parental RNA interference (pRNAi) in insects: mechanisms, applications, and challenges in pest management.Molecular biology reports · 2025Review
- Insect Pest Control from Chemical to Biotechnological Approach: Constrains and Challenges.Insects · 2025Review
- Functional Analysis of CPSF30 inInsects · 2024Article
- Effects of miR-306 Perturbation on Life Parameters in the English Grain Aphid,International journal of molecular sciences · 2024Article
- Neutral Dietary Effects of Two MicroRNAs, Csu-Novel-260 and Csu-Mir-14, on the Non-Target ArthropodPlants (Basel, Switzerland) · 2023Article
- Characterization and Functional Analysis ofInsects · 2023Article
- Development of RNAi Methods for the Mormon Cricket,Insects · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
RNA interference (RNAi) selectively targets genes and silences their expression in vivo, causing developmental defects, mortality and altered behavior. Consequently, RNAi has emerged as a promising research area for insect pest management. However, it is not yet a viable alternative over conventional pesticides despite several theoretical advantages in safety and specificity. As a first step toward a more standardized approach, a machine learning algorithm was used to identify factors that predict trial efficacy. Current research on RNAi for pest management is highly variable and relatively unstandardized. The applied random forest model was able to reliably predict mortality ranges based on bioassay parameters with 72.6% accuracy. Response time and target gene were the most important variables in the model, followed by applied dose, double-stranded RNA (dsRNA) construct size and target species, further supported by generalized linear mixed effect modeling. Our results identified informative trends, supporting the idea that basic principles of toxicology apply to RNAi bioassays and provide initial guidelines standardizing future research similar to studies of traditional insecticides. We advocate for training that integrates genetic, organismal, and toxicological approaches to accelerate the development of RNAi as an effective tool for pest management. © 2022 The Authors. Pest Management Science published by John Wiley & Sons Ltd on behalf of Society of Chemical Industry.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.